Botanic Healthcare®, a globally trusted manufacturer of science-backed nutraceutical ingredients, has announced the publication of new clinical data confirming the superior bioavailability of Lipomac™, its clinically engineered liposomal vitamin C developed using patented DFS Technology™.
Clinical Study Confirms Enhanced Absorption and Circulation
The randomized, open-label, crossover clinical study evaluated the pharmacokinetics of Lipomac™ in comparison with conventional non-liposomal vitamin C in 12 healthy adult subjects. The results showed significantly higher systemic exposure following Lipomac™ supplementation. In addition, the findings confirmed enhanced absorption, improved gastrointestinal transit, and prolonged circulation of vitamin C in the body.
Together, these outcomes provide robust human evidence that Lipomac™ effectively overcomes the inherent absorption limitations associated with conventional vitamin C formulations.
Study Design and Key Findings
As per the press release, the study followed a randomized, open-label, crossover design, allowing direct comparison between Lipomac™ liposomal vitamin C and standard non-liposomal vitamin C in the same participants. As a result, Lipomac™ demonstrated markedly higher bioavailability and greater systemic exposure, reinforcing the clinical advantages of liposomal delivery.
Why Liposomal Delivery Matters
Conventional vitamin C is highly susceptible to chemical and enzymatic degradation within the digestive tract, which significantly limits the amount that reaches systemic circulation. In contrast, liposomal delivery systems encapsulate the active ingredient within biocompatible phospholipid vesicles. This approach protects vitamin C from degradation, enhances intestinal absorption, and improves delivery into the bloodstream.
Consequently, this clinical validation reinforces liposomal technology as an effective and scalable platform for nutraceuticals that require enhanced uptake and biological efficiency.
DFS Technology™ and the Lipsobio® Platform
Botanic Healthcare developed Lipomac™ using its proprietary DFS Technology™, a patented platform engineered to stabilise sensitive actives, enable targeted delivery, and maximise biological performance. Lipomac™ forms part of Lipsobio®, the company’s advanced portfolio of liposomal ingredients spanning vitamins, minerals, nutraceuticals, and botanical actives.
Importantly, Lipsobio® authenticates each ingredient through Cryo-EM/TEM imaging, nanoscale structural mapping, stability and encapsulation profiling, in-vitro absorption studies, and clinical validation, setting a high scientific benchmark within the nutraceutical industry.
Leadership Perspectives on the Findings
Commenting on the results, Dr. H. N. Shivaprasad, Chief Scientific Officer, Botanic Healthcare®, said that the findings validate the scientific engineering behind DFS Technology™ and clearly demonstrate the measurable performance advantages of liposomal formats.
Meanwhile, Mr. Gaurav Soni, Founder and Managing Director, stated that Lipomac™ reflects the company’s commitment to clinically backed innovation and strengthens its position as a science-forward partner to global nutraceutical brands.
Adding to this, Mr. Madhu Krishnamani, Founder and Managing Director, said the company remains focused on advancing evidence-based solutions that deliver meaningful value to consumers worldwide.
Strengthening an Evidence-Driven Nutraceutical Portfolio
Overall, the publication of this clinical data further reinforces Botanic Healthcare’s expanding portfolio of evidence-driven nutraceutical ingredients. Moreover, it underscores the company’s continued commitment to translating advanced delivery technologies into clinically meaningful health solutions for global partners.